Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
ITOVEBI (INAVOLISIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
ITOVEBI
NDA
Get alerts
INAVOLISIB | N219249 | GENENTECH INC
2 strengths
7 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
7 unique patents, 1 exclusivity by expiration date
All strengths
3MG
9MG
Active (7)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
Today
8242104
Sep. 27, 2030
8343955
Sep. 27, 2030
9650393
Jul. 1, 2036
10851091
Jul. 1, 2036
11028100
Apr. 26, 2038
11760753
Jul. 1, 2036
12410189
Jun. 14, 2038
NCE
Oct. 10, 2029
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 3MG
RLD
7 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Oct 10, 2024
Patents (7)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8242104
Sep 27, 2030
—
Yes
Yes
—
—
8343955
Sep 27, 2030
—
—
—
U-4024
COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
—
9650393
Jul 1, 2036
—
Yes
Yes
U-4024
COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
—
10851091
Jul 1, 2036
—
Yes
Yes
—
—
11028100
Apr 26, 2038
—
Yes
Yes
—
—
11760753
Jul 1, 2036
—
—
—
U-4024
COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
—
12410189
Jun 14, 2038
—
—
—
U-4024
COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
—
Exclusivities (1)
Code
Date
Status
NCE
Oct 10, 2029
Active
#002 — 9MG
RLD
7 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Oct 10, 2024